{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import pandas as pd\n",
    "import time\n",
    "import json\n",
    "from datetime import datetime\n",
    "import string"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_drug_name(drug_name):\n",
    "    table = str.maketrans(dict.fromkeys(string.punctuation))\n",
    "    drug_name_parsed = drug_name.translate(table)\n",
    "    drug_name = drug_name.replace(\"-\", \" \")\n",
    "    drug_name = drug_name.lower()\n",
    "    #tokens = nltk.word_tokenize(drug_name)\n",
    "    #tokens = set(tokens)\n",
    "    \n",
    "    return drug_name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# method for getting clinicaltrials.gov info for given company\n",
    "def get_clinical_trials(company_name):\n",
    "    \n",
    "    ## clinicaltrials.gov searcher\n",
    "    clintrials_base_url = \"https://clinicaltrials.gov/api/query/study_fields\"\n",
    "    expr = \"'\" + company_name + \"'\"    \n",
    "    \n",
    "    fmt = \"JSON\"\n",
    "    min_rnk = 1\n",
    "    max_rnk = 1000\n",
    "    fields1 = ','.join([\n",
    "        'OrgFullName',\n",
    "        'NCTId',\n",
    "        'BriefTitle',\n",
    "        'OfficialTitle',\n",
    "        'DesignAllocation',\n",
    "        'Acronym',\n",
    "        'Phase',\n",
    "        'OverallStatus',\n",
    "        'DesignMasking',\n",
    "        'StartDate',\n",
    "        'EnrollmentCount',\n",
    "        'EnrollmentType',\n",
    "        'ArmGroupDescription',\n",
    "        'ArmGroupInterventionName',\n",
    "        'ArmGroupLabel',\n",
    "        'ArmGroupType',\n",
    "        'InterventionType',\n",
    "        'InterventionName',\n",
    "        'InterventionDescription',\n",
    "        'InterventionArmGroupLabel'\n",
    "    ])\n",
    "\n",
    "    fields2 = ','.join([\n",
    "        'PrimaryOutcomeMeasure',\n",
    "        'NCTId',\n",
    "        'PrimaryOutcomeDescription',\n",
    "        'PrimaryOutcomeTimeFrame',\n",
    "        'SecondaryOutcomeMeasure',\n",
    "        'SecondaryOutcomeDescription',\n",
    "        'SecondaryOutcomeTimeFrame',\n",
    "        'EligibilityCriteria',\n",
    "        'ConditionMeshId',\n",
    "        'ConditionMeshTerm',\n",
    "        'InterventionMeshId',\n",
    "        'InterventionMeshTerm',\n",
    "        'InterventionAncestorId',\n",
    "        'InterventionAncestorTerm',\n",
    "        'InterventionBrowseLeafId',\n",
    "        'InterventionBrowseLeafName',\n",
    "        'InterventionBrowseLeafAsFound',\n",
    "        'InterventionBrowseLeafRelevance',\n",
    "        'PrimaryCompletionDate',\n",
    "        'CompletionDate'    \n",
    "    ])\n",
    "\n",
    "    fields3 = ','.join([\n",
    "        'LeadSponsorName',\n",
    "        'NCTId',\n",
    "        'ResponsiblePartyType',\n",
    "        'LeadSponsorClass',\n",
    "        'IsFDARegulatedDrug',\n",
    "        'BriefSummary',\n",
    "        'DetailedDescription',\n",
    "        'Condition',\n",
    "        'Keyword',\n",
    "        'StudyType',\n",
    "        'DesignInterventionModel',\n",
    "        'DesignPrimaryPurpose'\n",
    "    ])\n",
    "\n",
    "    clin_payload1 = {\"expr\": expr, \"min_rnk\": min_rnk, \"max_rnk\": max_rnk, \"fmt\": fmt, \"fields\": fields1}\n",
    "    clin_payload2 = {\"expr\": expr, \"min_rnk\": min_rnk, \"max_rnk\": max_rnk, \"fmt\": fmt, \"fields\": fields2}\n",
    "    clin_payload3 = {\"expr\": expr, \"min_rnk\": min_rnk, \"max_rnk\": max_rnk, \"fmt\": fmt, \"fields\": fields3}\n",
    "    # make sure to add quotes to all terms so results are required to match\n",
    "    \n",
    "    clin_r1 = requests.get(clintrials_base_url, params=clin_payload1)\n",
    "    clin_r2 = requests.get(clintrials_base_url, params=clin_payload2)\n",
    "    clin_r3 = requests.get(clintrials_base_url, params=clin_payload3)\n",
    "    \n",
    "    clin_r1_dict = clin_r1.json()[\"StudyFieldsResponse\"][\"StudyFields\"]\n",
    "    for r1_dict in clin_r1_dict:\n",
    "        for r1_key in r1_dict:\n",
    "            if isinstance(r1_dict[r1_key], list):\n",
    "                r1_dict[r1_key] = \", \".join(r1_dict[r1_key])\n",
    "    \n",
    "    clin_r2_dict = clin_r2.json()[\"StudyFieldsResponse\"][\"StudyFields\"]\n",
    "    for r2_dict in clin_r2_dict:\n",
    "        for key in r2_dict:\n",
    "            if isinstance(r2_dict[key], list):\n",
    "                r2_dict[key] = \", \".join(r2_dict[key])\n",
    "    \n",
    "    clin_r3_dict = clin_r3.json()[\"StudyFieldsResponse\"][\"StudyFields\"]\n",
    "    for r3_dict in clin_r3_dict:\n",
    "        for key in r3_dict:\n",
    "            if isinstance(r3_dict[key], list):\n",
    "                r3_dict[key] = \", \".join(r3_dict[key])\n",
    "    \n",
    "    try:\n",
    "        \n",
    "        if \"StudyFields\" in clin_r1.json()[\"StudyFieldsResponse\"]:\n",
    "\n",
    "            if clin_r1.status_code == 200:\n",
    "                clin1_df = pd.DataFrame(clin_r1_dict)\n",
    "            else:\n",
    "                clin1_df = pd.DataFrame()\n",
    "            if clin_r2.status_code == 200:\n",
    "                clin2_df = pd.DataFrame(clin_r2_dict)\n",
    "            else:\n",
    "                clin2_df = pd.DataFrame()\n",
    "            if clin_r3.status_code == 200:\n",
    "                clin3_df = pd.DataFrame(clin_r3_dict)\n",
    "            else:\n",
    "                clin3_df = pd.DataFrame()\n",
    "\n",
    "            list_clin1_org = []\n",
    "            for row in clin1_df['OrgFullName']:\n",
    "                list_clin1_org.append(row)\n",
    "\n",
    "            list_clin1_nct = []\n",
    "            for row in clin1_df['NCTId']:\n",
    "                list_clin1_nct.append(row)\n",
    "\n",
    "            list_clin2_nct = []\n",
    "            for row in clin2_df['NCTId']:\n",
    "                list_clin2_nct.append(row)\n",
    "\n",
    "            list_clin3_nct = []\n",
    "            for row in clin3_df['NCTId']:\n",
    "                list_clin3_nct.append(row)\n",
    "\n",
    "            clin1_df[\"Company_name\"] = list_clin1_org\n",
    "            clin1_df[\"NCT_ID_new\"] = list_clin1_nct\n",
    "            clin2_df[\"NCT_ID_new\"] = list_clin2_nct\n",
    "            clin3_df[\"NCT_ID_new\"] = list_clin3_nct\n",
    "            clin3_df[\"EDGAR_name\"] = company_name\n",
    "\n",
    "            clin_all_df = clin1_df.join(clin2_df.set_index(\"NCT_ID_new\"), on=\"NCT_ID_new\", rsuffix=\"_2\").join(clin3_df.set_index(\"NCT_ID_new\"), on=\"NCT_ID_new\", rsuffix=\"_3\")\n",
    "\n",
    "            clin_all_df = clin_all_df[clin_all_df[\"Company_name\"].str.contains(company_name, case=False)]\n",
    "\n",
    "            return clin_all_df\n",
    "\n",
    "        else:\n",
    "            clin_all_df = pd.DataFrame()\n",
    "            return clin_all_df\n",
    "    \n",
    "    except:\n",
    "        \n",
    "        empty_df = pd.DataFrame()\n",
    "        \n",
    "        return \"error\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clinical_trials_with_drug(trials_df, drug_names):\n",
    "    filtered_trials = []\n",
    "    trials_df_dict = trials_df.to_dict('records')\n",
    "    for i in trials_df_dict:\n",
    "        for drug_name in drug_names:\n",
    "            if parse_drug_name(drug_name) in parse_drug_name(i[\"InterventionName\"]):\n",
    "                filtered_trials.append(i)\n",
    "    \n",
    "    filtered_trials_df = pd.DataFrame(filtered_trials)\n",
    "    \n",
    "    return filtered_trials_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# company name is string, drug_names (optional) is list\n",
    "def clinical_trials_company_drugs(company_name, drug_names=[]):\n",
    "    \n",
    "    co_trials = get_clinical_trials(company_name)\n",
    "    \n",
    "    if co_trials.empty:\n",
    "        \n",
    "        return \"no trials for company, check spelling of company name\"\n",
    "    \n",
    "    else:\n",
    "        \n",
    "        if drug_names:\n",
    "    \n",
    "            trials = clinical_trials_with_drug(co_trials, drug_names)\n",
    "\n",
    "            return trials\n",
    "        else:\n",
    "            \n",
    "            return co_trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>OfficialTitle</th>\n",
       "      <th>DesignAllocation</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Phase</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>DesignMasking</th>\n",
       "      <th>...</th>\n",
       "      <th>LeadSponsorClass</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>BriefSummary</th>\n",
       "      <th>DetailedDescription</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>DesignInterventionModel</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EDGAR_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT01619839</td>\n",
       "      <td>A Phase 2 Study To Assess The Efficacy, Tolera...</td>\n",
       "      <td>A Phase 2, Enriched-Enrollment, Randomized-Wit...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Quadruple</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>NKTR-181 is being developed as an analgesic co...</td>\n",
       "      <td></td>\n",
       "      <td>Osteoarthritis of the Knee</td>\n",
       "      <td>Nektar, NKTR-181</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT01492101</td>\n",
       "      <td>The BEACON Study (Breast Cancer Outcomes With ...</td>\n",
       "      <td>The BEACON Study (Breast Cancer Outcomes With ...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>BEACON</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The study is designed as an open-label, random...</td>\n",
       "      <td></td>\n",
       "      <td>Locally Recurrent Breast Cancer, Metastatic Br...</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03729245</td>\n",
       "      <td>A Study of Bempegaldesleukin (NKTR-214: BEMPEG...</td>\n",
       "      <td>A Phase 3 Randomized Open Label Study to Compa...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td></td>\n",
       "      <td>Renal Cell Carcinoma, Metastatic Renal Cell Ca...</td>\n",
       "      <td>Kidney Cancer, Kidney Neoplasms, Renal Cancer,...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04136756</td>\n",
       "      <td>NKTR-255 in Relapsed/Refractory Multiple Myelo...</td>\n",
       "      <td>A Phase 1, Open-label, Multi-center, Dose Esca...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Patients will receive intravenous (IV) NKTR-25...</td>\n",
       "      <td>NKTR-255 is a cytokine that is designed to reg...</td>\n",
       "      <td>Multiple Myeloma, Non-Hodgkin Lymphoma, Indole...</td>\n",
       "      <td>relapsed, refractory, NKTR-255, CAR-T, daratum...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03435640</td>\n",
       "      <td>A Study of NKTR-262 in Combination With Bempeg...</td>\n",
       "      <td>A Phase 1/2, Open-label, Multicenter, Dose Esc...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>REVEAL</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Patients will receive intra-tumoral (IT) NKTR-...</td>\n",
       "      <td>Cancer treatments that couple pharmacological ...</td>\n",
       "      <td>Melanoma, Merkel Cell Carcinoma, Triple Negati...</td>\n",
       "      <td>Bempegaldesleukin (NKTR-214), NKTR-262, Nivolu...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04646044</td>\n",
       "      <td>A Placebo Controlled Trial of Bempegaldesleuki...</td>\n",
       "      <td>A Phase 1b, Multicenter, Randomized, Double-Bl...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Double</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this phase-1b, multicenter...</td>\n",
       "      <td></td>\n",
       "      <td>Covid-19, Coronavirus Disease 2019</td>\n",
       "      <td>BEMPEG, Bempegaldesleukin, CD122, CD122-Biased...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02983045</td>\n",
       "      <td>A Dose Escalation and Cohort Expansion Study o...</td>\n",
       "      <td>A Phase 1/2, Open-label, Multicenter Study of ...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>PIVOT-02</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>In this four-part study, NKTR-214 will be admi...</td>\n",
       "      <td>NKTR-214 (investigational agent) is an IL-2 pa...</td>\n",
       "      <td>Melanoma, Renal Cell Carcinoma, Non Small Cell...</td>\n",
       "      <td>NKTR-214, Bempegaldesleukin, Nivolumab, Ipilim...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04616196</td>\n",
       "      <td>Study of NKTR 255 in Combination With Cetuxima...</td>\n",
       "      <td>A Phase 1b/2, Open-label, Multicenter, Dose Es...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Patients with relapsed or refractory (R/R) hea...</td>\n",
       "      <td>This study is a Phase 1b/2, open-label, multic...</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma (HNSCC),...</td>\n",
       "      <td>HNSCC, CRC, R/R, NKTR-255, Cetuximab</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03138889</td>\n",
       "      <td>A Study of a CD122-Biased Cytokine (NKTR-214) ...</td>\n",
       "      <td>A Phase 1/2, Open-Label, Multicenter Study to ...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>PROPEL</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>This study is to assess the safety and tolerab...</td>\n",
       "      <td>NKTR-214 is a cytokine (investigational agent)...</td>\n",
       "      <td>Non-Small Cell Lung Cancer, Melanoma, Urotheli...</td>\n",
       "      <td>NKTR-214, Metastatic Urothelial Bladder Cancer...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of N...</td>\n",
       "      <td>A Multicenter, Open-Label, Phase 2 Study to Ev...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This is a multicenter, open-label, two-arm, 2-...</td>\n",
       "      <td></td>\n",
       "      <td>Tumor, Breast Cancer</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT00598975</td>\n",
       "      <td>A Phase 2a/2b Multicenter, Open-Label Study to...</td>\n",
       "      <td>A Multicenter, Open-Label, Phase 2 Study to De...</td>\n",
       "      <td>N/A</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>Study 07-PIR-02 is a Phase 2 study designed to...</td>\n",
       "      <td>The Phase 2a portion of this study is complete...</td>\n",
       "      <td>Tumor, Colorectal Cancer</td>\n",
       "      <td>Phase 2a: Multiple solid tumor types, Phase 2b...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04410445</td>\n",
       "      <td>Study to Compare Adjuvant Immunotherapy of Bem...</td>\n",
       "      <td>A Phase 3, Randomized, Open-label Study to Com...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>PIVOT-12</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td>Melanoma, Melanoma Stage III, Melanoma Stage I...</td>\n",
       "      <td>CD122-Biased Agonist, CD122-Biased Cytokine, I...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT01457118</td>\n",
       "      <td>An Extension Study of NKTR-102 in Cancer Patie...</td>\n",
       "      <td>An Open-Label, Multicenter, Extension Study of...</td>\n",
       "      <td>N/A</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The study objective of this open label, multic...</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Solid Tumor</td>\n",
       "      <td>Open Label multicenter extension study advance...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT00856375</td>\n",
       "      <td>NKTR-102 Versus Irinotecan in Patients With Se...</td>\n",
       "      <td>A Multicenter, Open-Label, Randomized, Phase 2...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This study will evaluate whether NKTR-102, an ...</td>\n",
       "      <td></td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>colorectal cancer, Colorectal cancer, second line</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT00806156</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of N...</td>\n",
       "      <td>A Multicenter, Open-Label, Phase 2 Study to Ev...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This is a multicenter, open-label, two-arm, 2-...</td>\n",
       "      <td></td>\n",
       "      <td>Tumor, Ovarian Cancer</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03785925</td>\n",
       "      <td>A Single-Arm Study of Bempegaldesleukin (NKTR-...</td>\n",
       "      <td>A Phase 2, Single-Arm Study of Bempegaldesleuk...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>PIVOT-10</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to evaluate ...</td>\n",
       "      <td></td>\n",
       "      <td>Urinary Bladder Neoplasm, Neoplasm Metastasis</td>\n",
       "      <td>Bladder, Bladder Cancer, CD122, Cisplatin Inel...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT01991678</td>\n",
       "      <td>A Study in Cancer Patients With Hepatic Impair...</td>\n",
       "      <td>An Open-Label, Parallel-Group, Multicenter, Ph...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The purpose of this study is to investigate th...</td>\n",
       "      <td>Safety and PK data from patients with mild, mo...</td>\n",
       "      <td>Advanced or Metastatic Solid Tumors in Patient...</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT01976143</td>\n",
       "      <td>A Study in Cancer Patients to Evaluate the Eff...</td>\n",
       "      <td>A Phase 1 Study to Evaluate the Effect of Nktr...</td>\n",
       "      <td>N/A</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The purpose of this research study is to evalu...</td>\n",
       "      <td>This is an open-label study that will assess t...</td>\n",
       "      <td>Advanced Cancer, Metastatic Solid Tumors</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02915744</td>\n",
       "      <td>A Study of Etirinotecan Pegol (NKTR-102) Versu...</td>\n",
       "      <td>A Phase 3 Open-Label, Randomized, Multicenter ...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>ATTAIN</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This is an open-label, randomized, active comp...</td>\n",
       "      <td>This is an open-label, randomized, active comp...</td>\n",
       "      <td>Metastasis, Breast Cancer</td>\n",
       "      <td>Breast Cancer Brain Metastases (BCBM), Carcinoma</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02362672</td>\n",
       "      <td>Efficacy and Safety Study of NKTR-181 in Opioi...</td>\n",
       "      <td>A Phase 3 Double-Blind, Placebo-Controlled Stu...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>SUMMIT-07</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Quadruple</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The purpose of this study is to determine whet...</td>\n",
       "      <td>This is an enriched enrollment, randomized wit...</td>\n",
       "      <td>Low Back Pain, Chronic Pain</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02367820</td>\n",
       "      <td>Long-Term Safety and Tolerability Study of NKT...</td>\n",
       "      <td>A Phase 3 Multicenter, Open-Label, 52-Week Stu...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>SUMMIT-LTS</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>The purpose of this 52-week open label study i...</td>\n",
       "      <td>This is an open-label safety and tolerability ...</td>\n",
       "      <td>Low Back Pain, Chronic Pain</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03802227</td>\n",
       "      <td>A Study Using Functional Magnetic Resonance Im...</td>\n",
       "      <td>A Phase 1 Double-Blind, Double-Dummy, Parallel...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Triple</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to evaluate ...</td>\n",
       "      <td>This study is a single-center study in which a...</td>\n",
       "      <td>Moderate to Severe Chronic Pain</td>\n",
       "      <td></td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Basic Science</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02869295</td>\n",
       "      <td>A Phase 1/2 Multicenter Dose Escalation and Ex...</td>\n",
       "      <td>An Open-Label, Multicenter, Dose Escalation An...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>NKTR-214</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This is a first in human, open-label, sequenti...</td>\n",
       "      <td></td>\n",
       "      <td>Unspecified Adult Solid Tumor, Protocol Specific</td>\n",
       "      <td>Metastatic Solid Tumors, Locally Advanced Soli...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>23 rows × 58 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Rank          OrgFullName        NCTId  \\\n",
       "0      1  Nektar Therapeutics  NCT01619839   \n",
       "1      2  Nektar Therapeutics  NCT01492101   \n",
       "2      3  Nektar Therapeutics  NCT03729245   \n",
       "3      4  Nektar Therapeutics  NCT04136756   \n",
       "4      5  Nektar Therapeutics  NCT03435640   \n",
       "5      6  Nektar Therapeutics  NCT04646044   \n",
       "6      7  Nektar Therapeutics  NCT02983045   \n",
       "7      8  Nektar Therapeutics  NCT04616196   \n",
       "8      9  Nektar Therapeutics  NCT03138889   \n",
       "9     10  Nektar Therapeutics  NCT00802945   \n",
       "10    11  Nektar Therapeutics  NCT00598975   \n",
       "11    12  Nektar Therapeutics  NCT04410445   \n",
       "12    13  Nektar Therapeutics  NCT01457118   \n",
       "13    14  Nektar Therapeutics  NCT00856375   \n",
       "14    15  Nektar Therapeutics  NCT00806156   \n",
       "15    16  Nektar Therapeutics  NCT03785925   \n",
       "16    17  Nektar Therapeutics  NCT01991678   \n",
       "17    18  Nektar Therapeutics  NCT01976143   \n",
       "18    19  Nektar Therapeutics  NCT02915744   \n",
       "19    20  Nektar Therapeutics  NCT02362672   \n",
       "20    21  Nektar Therapeutics  NCT02367820   \n",
       "21    22  Nektar Therapeutics  NCT03802227   \n",
       "22    23  Nektar Therapeutics  NCT02869295   \n",
       "\n",
       "                                           BriefTitle  \\\n",
       "0   A Phase 2 Study To Assess The Efficacy, Tolera...   \n",
       "1   The BEACON Study (Breast Cancer Outcomes With ...   \n",
       "2   A Study of Bempegaldesleukin (NKTR-214: BEMPEG...   \n",
       "3   NKTR-255 in Relapsed/Refractory Multiple Myelo...   \n",
       "4   A Study of NKTR-262 in Combination With Bempeg...   \n",
       "5   A Placebo Controlled Trial of Bempegaldesleuki...   \n",
       "6   A Dose Escalation and Cohort Expansion Study o...   \n",
       "7   Study of NKTR 255 in Combination With Cetuxima...   \n",
       "8   A Study of a CD122-Biased Cytokine (NKTR-214) ...   \n",
       "9   Study to Evaluate the Safety and Efficacy of N...   \n",
       "10  A Phase 2a/2b Multicenter, Open-Label Study to...   \n",
       "11  Study to Compare Adjuvant Immunotherapy of Bem...   \n",
       "12  An Extension Study of NKTR-102 in Cancer Patie...   \n",
       "13  NKTR-102 Versus Irinotecan in Patients With Se...   \n",
       "14  Study to Evaluate the Safety and Efficacy of N...   \n",
       "15  A Single-Arm Study of Bempegaldesleukin (NKTR-...   \n",
       "16  A Study in Cancer Patients With Hepatic Impair...   \n",
       "17  A Study in Cancer Patients to Evaluate the Eff...   \n",
       "18  A Study of Etirinotecan Pegol (NKTR-102) Versu...   \n",
       "19  Efficacy and Safety Study of NKTR-181 in Opioi...   \n",
       "20  Long-Term Safety and Tolerability Study of NKT...   \n",
       "21  A Study Using Functional Magnetic Resonance Im...   \n",
       "22  A Phase 1/2 Multicenter Dose Escalation and Ex...   \n",
       "\n",
       "                                        OfficialTitle DesignAllocation  \\\n",
       "0   A Phase 2, Enriched-Enrollment, Randomized-Wit...       Randomized   \n",
       "1   The BEACON Study (Breast Cancer Outcomes With ...       Randomized   \n",
       "2   A Phase 3 Randomized Open Label Study to Compa...       Randomized   \n",
       "3   A Phase 1, Open-label, Multi-center, Dose Esca...   Non-Randomized   \n",
       "4   A Phase 1/2, Open-label, Multicenter, Dose Esc...   Non-Randomized   \n",
       "5   A Phase 1b, Multicenter, Randomized, Double-Bl...       Randomized   \n",
       "6   A Phase 1/2, Open-label, Multicenter Study of ...   Non-Randomized   \n",
       "7   A Phase 1b/2, Open-label, Multicenter, Dose Es...   Non-Randomized   \n",
       "8   A Phase 1/2, Open-Label, Multicenter Study to ...   Non-Randomized   \n",
       "9   A Multicenter, Open-Label, Phase 2 Study to Ev...       Randomized   \n",
       "10  A Multicenter, Open-Label, Phase 2 Study to De...              N/A   \n",
       "11  A Phase 3, Randomized, Open-label Study to Com...       Randomized   \n",
       "12  An Open-Label, Multicenter, Extension Study of...              N/A   \n",
       "13  A Multicenter, Open-Label, Randomized, Phase 2...       Randomized   \n",
       "14  A Multicenter, Open-Label, Phase 2 Study to Ev...       Randomized   \n",
       "15  A Phase 2, Single-Arm Study of Bempegaldesleuk...              N/A   \n",
       "16  An Open-Label, Parallel-Group, Multicenter, Ph...   Non-Randomized   \n",
       "17  A Phase 1 Study to Evaluate the Effect of Nktr...              N/A   \n",
       "18  A Phase 3 Open-Label, Randomized, Multicenter ...       Randomized   \n",
       "19  A Phase 3 Double-Blind, Placebo-Controlled Stu...       Randomized   \n",
       "20  A Phase 3 Multicenter, Open-Label, 52-Week Stu...              N/A   \n",
       "21  A Phase 1 Double-Blind, Double-Dummy, Parallel...       Randomized   \n",
       "22  An Open-Label, Multicenter, Dose Escalation An...              N/A   \n",
       "\n",
       "       Acronym             Phase           OverallStatus      DesignMasking  \\\n",
       "0                        Phase 2               Completed          Quadruple   \n",
       "1       BEACON           Phase 3               Completed  None (Open Label)   \n",
       "2                        Phase 3              Recruiting  None (Open Label)   \n",
       "3                        Phase 1              Recruiting  None (Open Label)   \n",
       "4       REVEAL  Phase 1, Phase 2              Recruiting  None (Open Label)   \n",
       "5                        Phase 1              Recruiting             Double   \n",
       "6     PIVOT-02  Phase 1, Phase 2  Active, not recruiting  None (Open Label)   \n",
       "7               Phase 1, Phase 2              Recruiting  None (Open Label)   \n",
       "8       PROPEL  Phase 1, Phase 2              Recruiting  None (Open Label)   \n",
       "9                        Phase 2               Completed  None (Open Label)   \n",
       "10                       Phase 2               Completed  None (Open Label)   \n",
       "11    PIVOT-12           Phase 3              Recruiting  None (Open Label)   \n",
       "12                       Phase 2               Completed  None (Open Label)   \n",
       "13                       Phase 2               Completed  None (Open Label)   \n",
       "14                       Phase 2               Completed  None (Open Label)   \n",
       "15    PIVOT-10           Phase 2  Active, not recruiting  None (Open Label)   \n",
       "16                       Phase 1               Completed  None (Open Label)   \n",
       "17                       Phase 1               Completed  None (Open Label)   \n",
       "18      ATTAIN           Phase 3               Completed  None (Open Label)   \n",
       "19   SUMMIT-07           Phase 3               Completed          Quadruple   \n",
       "20  SUMMIT-LTS           Phase 3               Completed  None (Open Label)   \n",
       "21                       Phase 1              Terminated             Triple   \n",
       "22    NKTR-214  Phase 1, Phase 2               Completed  None (Open Label)   \n",
       "\n",
       "    ... LeadSponsorClass IsFDARegulatedDrug  \\\n",
       "0   ...         INDUSTRY                      \n",
       "1   ...         INDUSTRY                      \n",
       "2   ...         INDUSTRY                Yes   \n",
       "3   ...         INDUSTRY                Yes   \n",
       "4   ...         INDUSTRY                Yes   \n",
       "5   ...         INDUSTRY                Yes   \n",
       "6   ...         INDUSTRY                Yes   \n",
       "7   ...         INDUSTRY                Yes   \n",
       "8   ...         INDUSTRY                Yes   \n",
       "9   ...         INDUSTRY                      \n",
       "10  ...         INDUSTRY                      \n",
       "11  ...         INDUSTRY                Yes   \n",
       "12  ...         INDUSTRY                      \n",
       "13  ...         INDUSTRY                      \n",
       "14  ...         INDUSTRY                      \n",
       "15  ...         INDUSTRY                Yes   \n",
       "16  ...         INDUSTRY                      \n",
       "17  ...         INDUSTRY                      \n",
       "18  ...         INDUSTRY                      \n",
       "19  ...         INDUSTRY                      \n",
       "20  ...         INDUSTRY                      \n",
       "21  ...         INDUSTRY                Yes   \n",
       "22  ...         INDUSTRY                      \n",
       "\n",
       "                                         BriefSummary  \\\n",
       "0   NKTR-181 is being developed as an analgesic co...   \n",
       "1   The study is designed as an open-label, random...   \n",
       "2   The main purpose of this study is to compare t...   \n",
       "3   Patients will receive intravenous (IV) NKTR-25...   \n",
       "4   Patients will receive intra-tumoral (IT) NKTR-...   \n",
       "5   The main purpose of this phase-1b, multicenter...   \n",
       "6   In this four-part study, NKTR-214 will be admi...   \n",
       "7   Patients with relapsed or refractory (R/R) hea...   \n",
       "8   This study is to assess the safety and tolerab...   \n",
       "9   This is a multicenter, open-label, two-arm, 2-...   \n",
       "10  Study 07-PIR-02 is a Phase 2 study designed to...   \n",
       "11  The main purpose of this study is to compare t...   \n",
       "12  The study objective of this open label, multic...   \n",
       "13  This study will evaluate whether NKTR-102, an ...   \n",
       "14  This is a multicenter, open-label, two-arm, 2-...   \n",
       "15  The main purpose of this study is to evaluate ...   \n",
       "16  The purpose of this study is to investigate th...   \n",
       "17  The purpose of this research study is to evalu...   \n",
       "18  This is an open-label, randomized, active comp...   \n",
       "19  The purpose of this study is to determine whet...   \n",
       "20  The purpose of this 52-week open label study i...   \n",
       "21  The main purpose of this study is to evaluate ...   \n",
       "22  This is a first in human, open-label, sequenti...   \n",
       "\n",
       "                                  DetailedDescription  \\\n",
       "0                                                       \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   NKTR-255 is a cytokine that is designed to reg...   \n",
       "4   Cancer treatments that couple pharmacological ...   \n",
       "5                                                       \n",
       "6   NKTR-214 (investigational agent) is an IL-2 pa...   \n",
       "7   This study is a Phase 1b/2, open-label, multic...   \n",
       "8   NKTR-214 is a cytokine (investigational agent)...   \n",
       "9                                                       \n",
       "10  The Phase 2a portion of this study is complete...   \n",
       "11  The main purpose of this study is to compare t...   \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16  Safety and PK data from patients with mild, mo...   \n",
       "17  This is an open-label study that will assess t...   \n",
       "18  This is an open-label, randomized, active comp...   \n",
       "19  This is an enriched enrollment, randomized wit...   \n",
       "20  This is an open-label safety and tolerability ...   \n",
       "21  This study is a single-center study in which a...   \n",
       "22                                                      \n",
       "\n",
       "                                            Condition  \\\n",
       "0                          Osteoarthritis of the Knee   \n",
       "1   Locally Recurrent Breast Cancer, Metastatic Br...   \n",
       "2   Renal Cell Carcinoma, Metastatic Renal Cell Ca...   \n",
       "3   Multiple Myeloma, Non-Hodgkin Lymphoma, Indole...   \n",
       "4   Melanoma, Merkel Cell Carcinoma, Triple Negati...   \n",
       "5                  Covid-19, Coronavirus Disease 2019   \n",
       "6   Melanoma, Renal Cell Carcinoma, Non Small Cell...   \n",
       "7   Head and Neck Squamous Cell Carcinoma (HNSCC),...   \n",
       "8   Non-Small Cell Lung Cancer, Melanoma, Urotheli...   \n",
       "9                                Tumor, Breast Cancer   \n",
       "10                           Tumor, Colorectal Cancer   \n",
       "11  Melanoma, Melanoma Stage III, Melanoma Stage I...   \n",
       "12                              Malignant Solid Tumor   \n",
       "13                                  Colorectal Cancer   \n",
       "14                              Tumor, Ovarian Cancer   \n",
       "15      Urinary Bladder Neoplasm, Neoplasm Metastasis   \n",
       "16  Advanced or Metastatic Solid Tumors in Patient...   \n",
       "17           Advanced Cancer, Metastatic Solid Tumors   \n",
       "18                          Metastasis, Breast Cancer   \n",
       "19                        Low Back Pain, Chronic Pain   \n",
       "20                        Low Back Pain, Chronic Pain   \n",
       "21                    Moderate to Severe Chronic Pain   \n",
       "22   Unspecified Adult Solid Tumor, Protocol Specific   \n",
       "\n",
       "                                              Keyword       StudyType  \\\n",
       "0                                    Nektar, NKTR-181  Interventional   \n",
       "1                                                      Interventional   \n",
       "2   Kidney Cancer, Kidney Neoplasms, Renal Cancer,...  Interventional   \n",
       "3   relapsed, refractory, NKTR-255, CAR-T, daratum...  Interventional   \n",
       "4   Bempegaldesleukin (NKTR-214), NKTR-262, Nivolu...  Interventional   \n",
       "5   BEMPEG, Bempegaldesleukin, CD122, CD122-Biased...  Interventional   \n",
       "6   NKTR-214, Bempegaldesleukin, Nivolumab, Ipilim...  Interventional   \n",
       "7                HNSCC, CRC, R/R, NKTR-255, Cetuximab  Interventional   \n",
       "8   NKTR-214, Metastatic Urothelial Bladder Cancer...  Interventional   \n",
       "9                                                      Interventional   \n",
       "10  Phase 2a: Multiple solid tumor types, Phase 2b...  Interventional   \n",
       "11  CD122-Biased Agonist, CD122-Biased Cytokine, I...  Interventional   \n",
       "12  Open Label multicenter extension study advance...  Interventional   \n",
       "13  colorectal cancer, Colorectal cancer, second line  Interventional   \n",
       "14                                                     Interventional   \n",
       "15  Bladder, Bladder Cancer, CD122, Cisplatin Inel...  Interventional   \n",
       "16                                                     Interventional   \n",
       "17                                                     Interventional   \n",
       "18   Breast Cancer Brain Metastases (BCBM), Carcinoma  Interventional   \n",
       "19                                                     Interventional   \n",
       "20                                                     Interventional   \n",
       "21                                                     Interventional   \n",
       "22  Metastatic Solid Tumors, Locally Advanced Soli...  Interventional   \n",
       "\n",
       "    DesignInterventionModel DesignPrimaryPurpose           EDGAR_name  \n",
       "0       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "1       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "2       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "3     Sequential Assignment            Treatment  Nektar Therapeutics  \n",
       "4       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "5       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "6       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "7     Sequential Assignment            Treatment  Nektar Therapeutics  \n",
       "8   Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "9       Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "10  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "11      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "12  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "13      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "14      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "15  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "16      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "17  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "18      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "19      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "20  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "21      Parallel Assignment        Basic Science  Nektar Therapeutics  \n",
       "22  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "\n",
       "[23 rows x 58 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clinical_trials_company_drugs(\"Nektar Therapeutics\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>OfficialTitle</th>\n",
       "      <th>DesignAllocation</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Phase</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>DesignMasking</th>\n",
       "      <th>...</th>\n",
       "      <th>LeadSponsorClass</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>BriefSummary</th>\n",
       "      <th>DetailedDescription</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>DesignInterventionModel</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EDGAR_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03729245</td>\n",
       "      <td>A Study of Bempegaldesleukin (NKTR-214: BEMPEG...</td>\n",
       "      <td>A Phase 3 Randomized Open Label Study to Compa...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td></td>\n",
       "      <td>Renal Cell Carcinoma, Metastatic Renal Cell Ca...</td>\n",
       "      <td>Kidney Cancer, Kidney Neoplasms, Renal Cancer,...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>5</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03435640</td>\n",
       "      <td>A Study of NKTR-262 in Combination With Bempeg...</td>\n",
       "      <td>A Phase 1/2, Open-label, Multicenter, Dose Esc...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>REVEAL</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Patients will receive intra-tumoral (IT) NKTR-...</td>\n",
       "      <td>Cancer treatments that couple pharmacological ...</td>\n",
       "      <td>Melanoma, Merkel Cell Carcinoma, Triple Negati...</td>\n",
       "      <td>Bempegaldesleukin (NKTR-214), NKTR-262, Nivolu...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04646044</td>\n",
       "      <td>A Placebo Controlled Trial of Bempegaldesleuki...</td>\n",
       "      <td>A Phase 1b, Multicenter, Randomized, Double-Bl...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td></td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Double</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this phase-1b, multicenter...</td>\n",
       "      <td></td>\n",
       "      <td>Covid-19, Coronavirus Disease 2019</td>\n",
       "      <td>BEMPEG, Bempegaldesleukin, CD122, CD122-Biased...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02983045</td>\n",
       "      <td>A Dose Escalation and Cohort Expansion Study o...</td>\n",
       "      <td>A Phase 1/2, Open-label, Multicenter Study of ...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>PIVOT-02</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>In this four-part study, NKTR-214 will be admi...</td>\n",
       "      <td>NKTR-214 (investigational agent) is an IL-2 pa...</td>\n",
       "      <td>Melanoma, Renal Cell Carcinoma, Non Small Cell...</td>\n",
       "      <td>NKTR-214, Bempegaldesleukin, Nivolumab, Ipilim...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>9</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03138889</td>\n",
       "      <td>A Study of a CD122-Biased Cytokine (NKTR-214) ...</td>\n",
       "      <td>A Phase 1/2, Open-Label, Multicenter Study to ...</td>\n",
       "      <td>Non-Randomized</td>\n",
       "      <td>PROPEL</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>This study is to assess the safety and tolerab...</td>\n",
       "      <td>NKTR-214 is a cytokine (investigational agent)...</td>\n",
       "      <td>Non-Small Cell Lung Cancer, Melanoma, Urotheli...</td>\n",
       "      <td>NKTR-214, Metastatic Urothelial Bladder Cancer...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>12</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT04410445</td>\n",
       "      <td>Study to Compare Adjuvant Immunotherapy of Bem...</td>\n",
       "      <td>A Phase 3, Randomized, Open-label Study to Com...</td>\n",
       "      <td>Randomized</td>\n",
       "      <td>PIVOT-12</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td>The main purpose of this study is to compare t...</td>\n",
       "      <td>Melanoma, Melanoma Stage III, Melanoma Stage I...</td>\n",
       "      <td>CD122-Biased Agonist, CD122-Biased Cytokine, I...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>16</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT03785925</td>\n",
       "      <td>A Single-Arm Study of Bempegaldesleukin (NKTR-...</td>\n",
       "      <td>A Phase 2, Single-Arm Study of Bempegaldesleuk...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>PIVOT-10</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The main purpose of this study is to evaluate ...</td>\n",
       "      <td></td>\n",
       "      <td>Urinary Bladder Neoplasm, Neoplasm Metastasis</td>\n",
       "      <td>Bladder, Bladder Cancer, CD122, Cisplatin Inel...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>23</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "      <td>NCT02869295</td>\n",
       "      <td>A Phase 1/2 Multicenter Dose Escalation and Ex...</td>\n",
       "      <td>An Open-Label, Multicenter, Dose Escalation An...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>NKTR-214</td>\n",
       "      <td>Phase 1, Phase 2</td>\n",
       "      <td>Completed</td>\n",
       "      <td>None (Open Label)</td>\n",
       "      <td>...</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td></td>\n",
       "      <td>This is a first in human, open-label, sequenti...</td>\n",
       "      <td></td>\n",
       "      <td>Unspecified Adult Solid Tumor, Protocol Specific</td>\n",
       "      <td>Metastatic Solid Tumors, Locally Advanced Soli...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>Nektar Therapeutics</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>8 rows × 58 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank          OrgFullName        NCTId  \\\n",
       "0     3  Nektar Therapeutics  NCT03729245   \n",
       "1     5  Nektar Therapeutics  NCT03435640   \n",
       "2     6  Nektar Therapeutics  NCT04646044   \n",
       "3     7  Nektar Therapeutics  NCT02983045   \n",
       "4     9  Nektar Therapeutics  NCT03138889   \n",
       "5    12  Nektar Therapeutics  NCT04410445   \n",
       "6    16  Nektar Therapeutics  NCT03785925   \n",
       "7    23  Nektar Therapeutics  NCT02869295   \n",
       "\n",
       "                                          BriefTitle  \\\n",
       "0  A Study of Bempegaldesleukin (NKTR-214: BEMPEG...   \n",
       "1  A Study of NKTR-262 in Combination With Bempeg...   \n",
       "2  A Placebo Controlled Trial of Bempegaldesleuki...   \n",
       "3  A Dose Escalation and Cohort Expansion Study o...   \n",
       "4  A Study of a CD122-Biased Cytokine (NKTR-214) ...   \n",
       "5  Study to Compare Adjuvant Immunotherapy of Bem...   \n",
       "6  A Single-Arm Study of Bempegaldesleukin (NKTR-...   \n",
       "7  A Phase 1/2 Multicenter Dose Escalation and Ex...   \n",
       "\n",
       "                                       OfficialTitle DesignAllocation  \\\n",
       "0  A Phase 3 Randomized Open Label Study to Compa...       Randomized   \n",
       "1  A Phase 1/2, Open-label, Multicenter, Dose Esc...   Non-Randomized   \n",
       "2  A Phase 1b, Multicenter, Randomized, Double-Bl...       Randomized   \n",
       "3  A Phase 1/2, Open-label, Multicenter Study of ...   Non-Randomized   \n",
       "4  A Phase 1/2, Open-Label, Multicenter Study to ...   Non-Randomized   \n",
       "5  A Phase 3, Randomized, Open-label Study to Com...       Randomized   \n",
       "6  A Phase 2, Single-Arm Study of Bempegaldesleuk...              N/A   \n",
       "7  An Open-Label, Multicenter, Dose Escalation An...              N/A   \n",
       "\n",
       "    Acronym             Phase           OverallStatus      DesignMasking  ...  \\\n",
       "0                     Phase 3              Recruiting  None (Open Label)  ...   \n",
       "1    REVEAL  Phase 1, Phase 2              Recruiting  None (Open Label)  ...   \n",
       "2                     Phase 1              Recruiting             Double  ...   \n",
       "3  PIVOT-02  Phase 1, Phase 2  Active, not recruiting  None (Open Label)  ...   \n",
       "4    PROPEL  Phase 1, Phase 2              Recruiting  None (Open Label)  ...   \n",
       "5  PIVOT-12           Phase 3              Recruiting  None (Open Label)  ...   \n",
       "6  PIVOT-10           Phase 2  Active, not recruiting  None (Open Label)  ...   \n",
       "7  NKTR-214  Phase 1, Phase 2               Completed  None (Open Label)  ...   \n",
       "\n",
       "  LeadSponsorClass IsFDARegulatedDrug  \\\n",
       "0         INDUSTRY                Yes   \n",
       "1         INDUSTRY                Yes   \n",
       "2         INDUSTRY                Yes   \n",
       "3         INDUSTRY                Yes   \n",
       "4         INDUSTRY                Yes   \n",
       "5         INDUSTRY                Yes   \n",
       "6         INDUSTRY                Yes   \n",
       "7         INDUSTRY                      \n",
       "\n",
       "                                        BriefSummary  \\\n",
       "0  The main purpose of this study is to compare t...   \n",
       "1  Patients will receive intra-tumoral (IT) NKTR-...   \n",
       "2  The main purpose of this phase-1b, multicenter...   \n",
       "3  In this four-part study, NKTR-214 will be admi...   \n",
       "4  This study is to assess the safety and tolerab...   \n",
       "5  The main purpose of this study is to compare t...   \n",
       "6  The main purpose of this study is to evaluate ...   \n",
       "7  This is a first in human, open-label, sequenti...   \n",
       "\n",
       "                                 DetailedDescription  \\\n",
       "0                                                      \n",
       "1  Cancer treatments that couple pharmacological ...   \n",
       "2                                                      \n",
       "3  NKTR-214 (investigational agent) is an IL-2 pa...   \n",
       "4  NKTR-214 is a cytokine (investigational agent)...   \n",
       "5  The main purpose of this study is to compare t...   \n",
       "6                                                      \n",
       "7                                                      \n",
       "\n",
       "                                           Condition  \\\n",
       "0  Renal Cell Carcinoma, Metastatic Renal Cell Ca...   \n",
       "1  Melanoma, Merkel Cell Carcinoma, Triple Negati...   \n",
       "2                 Covid-19, Coronavirus Disease 2019   \n",
       "3  Melanoma, Renal Cell Carcinoma, Non Small Cell...   \n",
       "4  Non-Small Cell Lung Cancer, Melanoma, Urotheli...   \n",
       "5  Melanoma, Melanoma Stage III, Melanoma Stage I...   \n",
       "6      Urinary Bladder Neoplasm, Neoplasm Metastasis   \n",
       "7   Unspecified Adult Solid Tumor, Protocol Specific   \n",
       "\n",
       "                                             Keyword       StudyType  \\\n",
       "0  Kidney Cancer, Kidney Neoplasms, Renal Cancer,...  Interventional   \n",
       "1  Bempegaldesleukin (NKTR-214), NKTR-262, Nivolu...  Interventional   \n",
       "2  BEMPEG, Bempegaldesleukin, CD122, CD122-Biased...  Interventional   \n",
       "3  NKTR-214, Bempegaldesleukin, Nivolumab, Ipilim...  Interventional   \n",
       "4  NKTR-214, Metastatic Urothelial Bladder Cancer...  Interventional   \n",
       "5  CD122-Biased Agonist, CD122-Biased Cytokine, I...  Interventional   \n",
       "6  Bladder, Bladder Cancer, CD122, Cisplatin Inel...  Interventional   \n",
       "7  Metastatic Solid Tumors, Locally Advanced Soli...  Interventional   \n",
       "\n",
       "   DesignInterventionModel DesignPrimaryPurpose           EDGAR_name  \n",
       "0      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "1      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "2      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "3      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "4  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "5      Parallel Assignment            Treatment  Nektar Therapeutics  \n",
       "6  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "7  Single Group Assignment            Treatment  Nektar Therapeutics  \n",
       "\n",
       "[8 rows x 58 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clinical_trials_company_drugs(\"Nektar Therapeutics\", [\"Bempegaldesleukin\", \"NKTR-214\"])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
